Company news: Shilpa Medicare

| Updated on December 04, 2019 Published on December 04, 2019

This image is used here for representational purpose only   -  Getty Images

Shilpa Medicare on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its facility in Raichur, Karnataka. An EIR is given to a unit on successful closure of an inspection conducted by the United States Food and Drug Administration (USFDA). The company announced successful closure of the inspection conducted at its active pharmaceutical ingredient (API) manufacturing site at Raichur with the receipt of EIR from the USFDA, Shilpa Medicare said in a filing to the BSE. The inspection was conducted from July 22-26, it added. The stock of Shilpa Medicare closed 2.86 per cent higher at ₹298.30 on the BSE.

Published on December 04, 2019
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.